Home  |   eJManager Journal Management System

Directory for Medical Articles
 

Open Access

Original Research

Med Arh. 2013; 67(5): 365-367


The Effects of Dipeptidyl Peptidase-4 Inhibitors in Treatment of Obese Patients with Type 2 Diabetes

Zelija Velija-Asimi, Sebija Izetbegovic, Jasenko Karamehic, Jozo Coric, Mirsad Panjeta, Amra Macic-Dzankovic, Jasminka Djelilovic-Vranic, mela Dizdarevic-Bostandzic.

Cited by (1)

Abstract
Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation of incretin hormones. Goal: To assess the effects of treatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus. Patients and methods: The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24±2,26 kg/m2, mean age 58 ±6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin. Results: After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was −1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients. Conclusion: These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.

Key words: Dipeptidyl peptidase-4 inhibitors, metformin, type 2 diabetes, obesity.


Full text links





ScopeMed Home
Follow ScopeMed on Twitter
Job Opportunities/Service Offers
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright © ScopeMed® International Medical Journal Management and Indexing System.